Patients with prostate cancer who are National Hospital Insurance Fund (NHIF) members will now have access to a critical medicine inside their current benefits package at a discounted price as reported by the Nation newspaper.
The pharmaceutical division of the Johnson & Johnson firm; Johnson & Johnson Middle East FZ-LLC (Janssen Kenya) produces and distributes the ground-breaking prescription medication.
An innovative treatment regimen called Abiraterone Acetate will be available to those with advanced prostate cancer thanks to a collaborative Memorandum of Understanding that NHIF and Janssen Kenya signed last week.
The price of the medication will be reduced by half from Ksh 1,200,000 under the arrangement, and a patient will receive 10 packets of the medication to fit inside the Ksh 600,000 NHIF oncology package.
This is despite the fact that the government continues to struggle with health financing, particularly for non-communicable diseases; which could thwart the implementation of universal health coverage.
The majority of donors concentrate on transmissible diseases like HIV/Aids; which puts a heavy burden on patients fighting chronic diseases like cancer, diabetes and hypertension.
Currently, the NHIF oncology package covers 20 sessions of radiotherapy at a cost of Ksh 3,600 per session, four sessions for second- and third-grade treatment at a cost of Ksh 150,000 each and six sessions of first-grade treatment at a cost of Ksh 25,000 each.
At the diagnosing level, biopsies and radiography including PET and CT scans, MRIs and ultrasounds performed under anaesthesia are catered for.
A maximum of two brachytherapy treatments per year are allowed for patients with advanced cancer along with oral and injectable anti-cancer medications, 10 chemotherapy sessions and other treatments.
These packages are provided in a few level five and six hospitals as well as a few chosen private hospitals; mostly in cities.
Content created and supplied by: MsLK (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More